Overall rank by patents
#42,213
Across all tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, active 2017–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES).
The verdict
Pegasor holds 6 US patents across 5 technology areas, rank #42,213 of 50,000 tracked assignees.
Pegasor OY has been granted 6 US utility patents between 2017 and 2023, placing Pegasor OY at rank #42,213 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.5 claims per patent with primary concentration in G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES). As a Foreign Corporation, Pegasor OY is one of the more focused assignees in the PatentsView dataset. By volume, Pegasor sits between PDS IG Holdings Llc (6 patents, rank #42,209) and Pelican Healthcare Limited (6 patents, rank #42,217) - the closest US assignees by grant volume. The composite Innovation Score of 24.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 4 in the 2015–2019 window, a -50% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Pegasor OY's 11.5 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Pegasor OY against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
PDS IG Holdings LLC
6 patents
PDX Pharmaceuticals, Inc.
6 patents
PEDIGO PRODUCTS, INC.
6 patents
PEDRALI S.p.A.
6 patents
PEINEMANN EQUIPMENT B.V.
6 patents
PEKING UNIVERSITY THIRD HOSPITAL
6 patents
PELEMAN INDUSTRIES, NAAMLOZE VENNOOTSCHAP
6 patents
PELICAN HEALTHCARE LIMITED
6 patents
PEGASOR OY
6 patents
What this shows Pegasor holds 6 patents at rank #42,213, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #42,213 in granted patent volume.
Other assignees with the most granted patents in Pegasor's primary technology class.
Pegasor's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
25 Top 84% higher than 16% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 3 | 50.0% |
| 2019 | 1 | 16.7% |
| 2020 | 1 | 16.7% |
| 2023 | 1 | 16.7% |
Top 5 of 5 technology areas
Overall rank by patents
#42,213
Across all tracked assignees
24.9 out of 100
How to use this portfolio
Pegasor's 6 grants land it in the top 84% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.